Our Mission
Utilize our innovative technology and deep expertise to offer specialized cancer tests preventing the endemic problem of cancer treatment failure which costs healthcare providers and patients billions of rupees and results in thousands of premature deaths every year.
Competitive Advantages:
-
Most accurate technology
-
ROI in 2 years or less
-
Significant savings for payors and patients
-
Simple & easy to use for management
-
Complimentary to existing platforms
First Markets:
-
Cancer diagnosis (Companion diagnosis)
-
Genetic disorders diagnosis
Future Markets:
-
Cancer therapeutics
-
Community screening
-
Pharmaco-genetic studies
Our Roadmap
The Solution
Bukhari Genomics has exclusive partnerships with top cancer diagnostics manufacturers to commercialize in Pakistan 12 specialized cancer tests that can be used to diagnose and screen as well as guide the selection of novel therapeutics for the treatment of various types of cancers.
We plan to commercialize this technology from the platform of the Bukhari Genomics clinical lab by offering tests and reports for all types of cancers.
Value Proposition
Our proposition is to use a combination of our novel test(s) and genomic expertise for accurate and early detection of cancer, allowing physicians to institute earlier treatment to prevent or stop disease progression to end-stage cancer.
In short, our technology offers concise methods for diagnosing and staging cancer, monitoring disease progression which allows for substantially improved treatment efficacy, and screening for the toxicity of conventional drugs in cancer hospitals.
Business Development
We have planned our business development efforts into two phases, the first phase will include research and development (R&D) related activities involving proof of concept testing as well as test optimization and regulatory approval.
The second phase will deal with operational and commercialization activities. For the second phase, we have the option of partnering with any interested cancer center, biopharma, or diagnostic company.
Entry Point
The entry into the biotech/diagnostic industry will focus on our technology and product positioning. Bukhari Genomics wants to deliver a solution that can be integrated with any existing cancer management and standard of care.
The company can achieve this goal by positioning our product as an add-on complementary assay to any existing cancer regimens. By implementing this strategy, our technology can be used by any of the healthcare providers or any diagnostic lab for old and new cancer therapies.